Respiratory medicine · 2026
Subcutaneous immunotherapy with house dust mite extract in Indonesian children with allergic rhinitis and asthma: A double-blind randomized controlled trial.
СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Putera Azwin Mengindra, Endaryanto Anang, Irwanto, Sari Iqlima Luthfita, Widitaputra Muhamad Abbud
Аннотация
BACKGROUND: Allergic rhinitis (AR) and asthma due to house dust mite (HDM) are increasing in children worldwide, including Indonesia, where the tropical environment favors HDM proliferation. Although Subcutaneous immunotherapy (SCIT) is widely used, local pediatric evidence remains limited.
OBJECTIVE: To evaluate the effect of HDM SCIT on clinical and immunological outcomes in children with AR and AR plus asthma.
METHODS: A double-blind randomized controlled trial was conducted in 41 children, divided into AR (n = 20) and AR + asthma (n = 21) groups. Participants received weekly HDM SCIT for 14 weeks. Total IgE, specific IgE, IL-10, TGF-β1, Combined Symptom Medication Score (CSMS), and Visual Analogue Scale (VAS) were measured before and after treatment. Statistical analyses included paired t-test, Wilcoxon, independent t-test, and Mann-Whitney, with significance at p < 0.05.
RESULTS: HDM SCIT significantly reduced total IgE, TGF-β1, CSMS, and VAS (p < 0.05). Specific IgE showed a downward trend without statistical significance. IL-10 levels slightly increased but were not significant (p = 0.683). No significant differences in treatment effect were observed between AR and AR + asthma groups (p > 0.05).
CONCLUSION: HDM SCIT improved clinical outcomes and reduced key immunological markers in children with AR and AR plus asthma, though no intergroup differences were found. These findings provide preliminary evidence supporting HDM SCIT as a safe and beneficial adjunct therapy in Indonesian pediatric populations.
OBJECTIVE: To evaluate the effect of HDM SCIT on clinical and immunological outcomes in children with AR and AR plus asthma.
METHODS: A double-blind randomized controlled trial was conducted in 41 children, divided into AR (n = 20) and AR + asthma (n = 21) groups. Participants received weekly HDM SCIT for 14 weeks. Total IgE, specific IgE, IL-10, TGF-β1, Combined Symptom Medication Score (CSMS), and Visual Analogue Scale (VAS) were measured before and after treatment. Statistical analyses included paired t-test, Wilcoxon, independent t-test, and Mann-Whitney, with significance at p < 0.05.
RESULTS: HDM SCIT significantly reduced total IgE, TGF-β1, CSMS, and VAS (p < 0.05). Specific IgE showed a downward trend without statistical significance. IL-10 levels slightly increased but were not significant (p = 0.683). No significant differences in treatment effect were observed between AR and AR + asthma groups (p > 0.05).
CONCLUSION: HDM SCIT improved clinical outcomes and reduced key immunological markers in children with AR and AR plus asthma, though no intergroup differences were found. These findings provide preliminary evidence supporting HDM SCIT as a safe and beneficial adjunct therapy in Indonesian pediatric populations.